ARRJF:OTC-Arjo AB (publ) (USD)

COMMON STOCK | Medical Distribution | OTC

Last Closing Price

USD 11.40

Change

0.00 (0.00)%

Market Cap

USD 3.10B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Arjo AB (publ) (ARRJF) Stock Analysis:
Based on the Arjo AB (publ) stock forecasts from 1 analysts, the average analyst target price for Arjo AB (publ) is USD 0.00 over the next 12 months. Arjo AB (publ)’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arjo AB (publ) is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Arjo AB (publ)’s stock price was USD 11.40. Arjo AB (publ)’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +42.09% over the last year.

No recent analyst target price found for Arjo AB (publ)
No recent average analyst rating found for Arjo AB (publ)

About

Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medic ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SHPMY Shanghai Pharmaceuticals Holdi..

N/A

USD7.94B 6.64 0.93
SHPMF Shanghai Pharmaceuticals Holdi..

N/A

USD7.94B 6.87 0.93
SHTDF Sinopharm Group Co. Ltd

-0.10 (-4.12%)

USD7.58B 6.25 0.61
SHTDY Sinopharm Group Co. Ltd

+0.05 (+0.40%)

USD7.33B 6.03 0.61
CAKFY McKesson Europe AG

N/A

USD5.54B 25.00 15.77
CAKFF McKesson Europe AG

N/A

USD5.54B 25.10 15.77
MAHLY MediPal Holdings Corporation

N/A

USD3.85B 15.35 0.03
CQCQ MakingORG Inc

N/A

USD0.03B N/A 19,792.40
EXHI Exlites Holdings International..

N/A

USD0.02B N/A N/A
PDRX PD-Rx Pharmaceuticals Inc

N/A

USD4.01M 15.00 N/A

ETFs Containing ARRJF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 42.09% 93% A 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.09% 93% A 77% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.51% 86% B 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.51% 86% B 67% D+
Risk Return Profile  
Volatility (Standard Deviation) 35.08% 43% F 61% D-
Risk Adjusted Return 109.78% 100% A+ 98% A+
Market Capitalization 3.10B 50% F 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 211.02 9% F 3% F
Price/Book Ratio 4.72 18% F 25% F
Price / Cash Flow Ratio 1.37 27% F 38% F
EV/EBITDA 1.63 36% F 61% D-
Management Effectiveness  
Return on Equity 11.90% 82% B- 70% C-
Return on Invested Capital 9.08% 62% D- 70% C-
Return on Assets 4.91% 85% B 79% C+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.01 86% B 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector